19 april 2017, ECN

New joint venture MOJI to fast track Dutch gasification technology commercialisation
ECN and partner Dahlman Renewable Technology (DRT) have launched a new joint venture to fast track the commercialisation of their gasification technology. MOJI technology efficiently converts a wide range of sustainable feedstocks to electricity, green gas, chemicals and even sustainable fuels. This is an exciting next step in enabling the transition to a sustainable energy system worldwide.

1 maart 2016, Diversen

The challenge to bring medicines to the market
Many IMM graduates pursue a career in academia. But just as many of them venture out into an industrial career to contribute to the valorization of scientific research. Silvie Meeuwissen is one of those scientists. After a successful but fundamental PhD project she preferred the more applied research at ChemConnection, a contract research and manufacturing company. From the state of the art laboratory of the company in Oss she tells us why.
This interview appeared in the 2015 annual report of the Nijmegen Institute of Molecules and Materials (IMM).

22 november 2012, NPC Highlights

Good to hear what is out there
Many NPC projects are coming to an end. The PhD students involved are about to be released onto the career market. Many of them are not sure about what to do after their graduation, as became clear when the application was opened of the BioBusiness Summerschool 2012. The summerschool introduces the students to 'the business world of Life Sciences'. As many as 70 PhDs attended the week long summerschool in Amsterdam to hear about opportunities in large companies, the possibilities to start a business and to have opportunities to extend their network.

1 april 2011, IOP

The quest for a cure for mitochondrial diseases
Jan Smeitink’s purpose in life is finding a cure for mitochondrial diseases. Every year he sees hundreds of children with genetic mitochondrial defects in his clinic. The majority of the kids do not live to be adults. The energy factories of their cells, the mitochondria, fail to produce enough energy for other cellular processes. The result is a plethora of multisystem diseases. The IOP Genomics project has resulted in the development of a high-throughput screening platform for live cells using state-of-the-art imaging techniques. Hundreds of potential drugs for mitochondrial disorders can be tested using this platform. In the near future, this will lead to a cure for some of the mitochondrial diseases.

30 april 2009, Interface

Construction and data mining of chemical and biological databases
Predicting biological activity of compounds accurately is of great importance in the development of new drugs. Not only bioinformatics methods are used to predict for example receptor interaction with a drug, but also cheminformatics methods to predict the possible toxicity of a potential drug molecule. Jeroen Kazius constructed extensive databases and designed new data mining methods which can more accurately predict such activities.

1 maart 2009, IOP

Cell wall dynamics of Aspergillus Niger
Aspergillus niger, well known as the fungus that produces black mold on old bread, forms an extended network of interconnected hyphae. This mycelium has an enormous capacity to secrete proteins and other compounds. Its productivity has led the food and pharmaceutical industry to use A. niger  as the preferred biological production factories for, among others, enzymes. New information about genetic signalling in the fungus cells has urged Marc van der Maarel to study the dynamics of the A. niger mycelium in more detail.

1 februari 2009, IOP

Why some people live longer than others
Not all old people are equally old. That is, their chronological age - the number of years they have lived - is not the same as their biological age - their life expectancy and health. Some people appear to have a hereditary taint for longevity. By studying a large group of very old people, who are obviously protected from ageing and disease, researchers are trying to find these genetic variations and the biomarkers by which they are expressed.

1 februari 2009, IOP

A screening platform to understand energy metabolism
Mitochondrial disorders are a group of serious, often fatal diseases. Due to a genetic defect, the powerhouses of our cells are unable to produce enough energy from food. The mechanisms are poorly understood, let alone a therapy being available for patients. Jan Smeitink works to understand the energy metabolism in mitochondria by setting up a screening platform. This platform should generate enough knowledge to influence the energy metabolism and eventually cure disorders associated with it.

1 oktober 2007, Conceptuur

How big will their success be?
Monoclonal antibodies are the quickly rising stars of cancer therapeutics. One of the first fully human therapeutic antibodies is developed by the partly Dutch biotech company Genmab. The first trials with this therapeutic, HuMax-CD20, show amazing results against B-cell chronic lymphocytic leukemia. Genmabs EVP and CSO Jan van de Winkel is thrilled about the success. "I think this is one of the best examples of an academic concept taken to the clinic."

1 oktober 2007, Conceptuur

Dextran microspheres release proteins where and when needed
A drug delivery system based on a dextran hydrogel is on the virge of commercialization. Prof.  Wim Hennink incorporates therapeutic proteins into dextran-based microspheres. These proteins are released by diffusion and degradation of the hydrogel. Timing of release is crucial and can be precisely tuned. Hennink has been working on this new system since the early nineties. The pharmaceutical company Octoplus is now 'valorizing' it by taking it to the clinic. "Valorisation is the translation step needed to go from academic concept to industrial product."

1 september 2006, Conceptuur

Let food be thy medicine
"Two-thirds of all medicine has a background in food. Research at the interface between food and pharma is important," says Dr. Johan Garssen. In a strategic alliance between Numico Research and the UIPS in Utrecht he investigates the influence of certain oligosaccharides in breast milk on the immune system. These sugars act as prebiotics and in one trial reduced the incidence of allergy in babies by half. "This group of oligosaccharides is capable of much more than we ever imagined."

1 augustus 2006, IOP

Dutch genomics research in good position to prosper
Prof. Dr. Arjen van Tunen stood at the cradle of the IOP Genomics programme at the dawn of the new millenium.  It was the first national Genomics research programme starting in the Netherlands. Van Tunen is content with the development of IOP Genomics since then, but urges the authorities to let go of traditional divisions: "THE industry and THE universities do not exist," van Tunen says. "Knowledge providers such as Keygene are in between. They should be acknowledged better for their merits and opportunities."